αvβ3 Integrin in angiogenesis and restenosis. Small molecules, peptides, peptidomimetics and antibodies are being developed as antagonists of angiogenic activity

Drug News and Perspectives

Volumn 14, Issue 3, 2001, Pages 143-150

  Kerr, J S ^a   Mousa, S A ^a   Slee, A M ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[[1 [3 (1H IMIDAZOL 2 YLAMINO)PROPYL] 1H INDAZOL 5 YL]CARBONYL]AMINO] N (MESITYLSULFONYL)ALANINE; ANTIBODY; CP 4632; CYCLOPEPTIDE; INTEGRIN; L 748415; SP 4632; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANGIOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CORONARY ARTERY OBSTRUCTION; EYE DISEASE; HEART FAILURE; HUMAN; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; RECURRENT DISEASE; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0034953628     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Arg-Gly-Asp: A versatile cell recognition sequence
2. Integrins: Versatility, modulation and signaling in cell adhesion
3. Integrins: Structure, function and biological properties
4. Signal transduction by integrins: Increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins
5. Cell adhesion or integrin clustering increased phosphorylation of a focal adhesion associated kinase
6. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation
7. pH regulation in spread and round cells
8. +/H antiporter by clustering and immobilizing integrin-alpha 5 beta 1, independent of cell shape
9. + antiporter by platelet-derived growth factor
10. Signal transduction by the platelet integrin alphaIIb/beta3: Induction of calcium oscillations required for protein-tyrosine phosphorylation and ligand-induced spreading of stably transfected cells
11. Spreading of human endothelial cells on fibronectin or vitronectin triggers elevation of intracellular free calcium
12. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms
13. Adhesion to fibronectin stimulates inositol lipid synthesis and enhances PDGF-induced inositol lipid breakdown
14. A link between cyclin expression and adhesion dependent cell cycle proliferation
15. Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fibronectin
16. Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules and selectins
17. Role of alpha v beta 3 integrin in the activation of vascular endothelial growth factor receptor-2
18. A mechanism for modulation of cellular responses for VEGF: Activation of integrins
19. Suppression of p53 activity and p21WAF/CIPI expression by vascular cell integrin alpha v beta 3 during angiogenesis
20. NF-κB mediates alpha v beta 3 integrin-induced endothelial cell survival
21. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
22. Functional activation of integrin alpha v beta 3 in tumor cells expressing membrane-type I matrix metalloproteinase
23. Disruption of matrix metalloproteinase 2 binding to integrin alpha v beta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
24. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin
25. Requirement of vascular integrin alpha v beta 3 for angiogenesis
26. cDNA sequence of the human integrin beta 5 subunit
27. Cloning, primary structure and properties of a novel human integrin beta subunit
28. Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion in kinase phosphorylation
29. Receptor tyrosine kinase signaling required for integrin alpha v beta 5 directed cell motility but not adhesion on vitronectin
30. Definition of two angiogenic pathways by distinct alpha v integrins
31. Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor
32. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice
33. Alpha-v/beta 3 and alpha-v/beta 5 integrin distribution in neoplastic kidney
34. Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas
35. Transient functional expression of alpha v beta 3 on vascular cells during wound repair
36. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin
37. Expression and function of endothelial cell alpha v integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras
38. Involvement of integrin alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases
39. Requirement of integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen
40. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment
41. Role of alpha v integrins during angiogenesis
42. Expression of alpha v beta 3 in small blood vessels of glioblastoma tumors
43. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells
44. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas
45. Involvement of integrin alpha v gene expression in human melanoma tumorigenicity
46. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival
47. Role of the alpha v beta 3 integrin in human melanoma cell invasion
48. Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin
49. Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression
50. Beta 3 integrin expression in melanoma predicts subsequent metastasis
51. Vascular integrin alpha v beta 3: A new prognostic indicator in breast cancer
52. Adhesion molecule profile and malignancy of melanocytic lesions
53. Tumor progression and metastatic behavior in vivo correlates with integrin expression on melanocytic tumors
54. Alpha v-integrins in human melanoma: Gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice
55. Involvement of integrin alpha v gene expression in human melanoma tumorigenicity
56. Role of alpha v integrins and vitronectin in human melanoma cell growth
57. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen
58. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo
59. Cancer treatment by targeted drug to tumor vasculature in a mouse model
60. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy
61. Magnetic resonance contrast enhancement of neovasculature with alpha v beta 3-targeted nanoparticles
62. Radiolabeled alpha v beta 3 integrin antagonists: A new class of tracers for tumor targeting
63. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide
64. Detection of tumor angiogenesis in vivo by alpha v beta 3-targeted magnetic resonance imaging
65. Integrin chatter and vascular function in diabetic retinopathy
66. Antagonists inhibit retinal neovascularization in a murine model
67. Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat
68. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques
69. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle in vitro
70. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro
71. Inhibition of neointimal hyperplasia by blocking alpha v beta 3 integrin with a small peptide antagonist GpenGRGDSPCA
72. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation
73. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits
74. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
75. Role of angiogenesis in patients with cerebral ischemic stroke
76. Activated microvessels express vascular endothelial growth factor and integrin alpha v beta 3 during focal cerebral ischemia
77. Integrin alpha v beta 3 is expressed in selected microvessels after focal cerebral ischemia
78. Histological appearance of the synovium in early rheumatoid arthritis
79. Angiogenesis in pannus formation
80. Adhesion molecule expression in human synovial tissue
81. Focally regulated endothelial proliferation and cell death in human synovium
82. Decreased angiogenesis and arthritic disease in rabbits treated with an alpha v beta 3 antagonist
83. Mice lacking B3 integrins are osteosclerotic because of dysfunctional osteoclasts
84. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone
85. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis
86. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption
87. Integrins and signaling in osteoclast function
88. The effect of SB 2730005, an orally active, non-peptide alpha v beta 3 vitronectin receptor antagonist in the adjuvant arthritic rat
89. Targeted apoptosis of synovial neovasculature I murine collagen-induced arthritis
90. The extracellular matrix as a cell survival factor
91. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
92. Selective cognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha v beta 3 and alpha 5 beta 1_integrins
93. Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries
94. Selection of peptides binding to the alpha 5 beta 1 integrin from a phage display library
95. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library
96. RGD and other recognition sequences for integrins
97. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
98. Synergy between a antiangiogenic integrin alpha v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
99. Integrins alpha v beta 3 and alpha v beta 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide
100. Conformation-activity studies of rationally designed potent anti-adhesive RGD peptides
101. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion
102. Type II to type Ib-turn swap changes specificity for integrins
103. Discovery of potent non-peptide vitronectin (alpha v beta 3 integrin) antagonists
104. Solid phase synthesis of a selective alpha v beta 3 integrin antagonist library
105. Design and synthesis of potent and selective peptidomimetic vitronectin receptor antagonists
106. A peptidomimetic antagonist of the integrin alpha(v) beta 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy
107. Disintegrins: A family of integrin inhibitory proteins from viper venoms
108. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors
109. Effect of four disintegrins on the adhesive and metastatic properties of B6F10 melanoma cells in a murine model
110. Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins
111. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity
112. Isoxazolines as potent antagonists of the integrin alpha v beta 3
113. Disubstituted indazoles as potent antagonists of the integrin alpha v beta 3
114. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic
115. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha v beta 3 integrin in human melanoma cells
116. Combinatorial chemistry techniques applied to non-peptide integrin antagonists
117. A specific sequence of the non-collagenous domain of the alpha v(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells
118. Ligands to the integrin receptor alpha v beta 3
119. Identification and in vivo efficacy of small-molecule antagonists of integrin alpha v beta 3 (the vitronectin receptor)
120. Angiogenesis at the interface between basic and clinical research
121. Antiangiogenic agents